# CVS HEALTH Corp: Form 10-Q for the period ended Mar 31, 2013

- Company: [CVS HEALTH Corp](/companies/cvs.md) (CIK 64803)
- Form: 10-Q
- Filed: 2013-05-01
- Accepted by EDGAR: May 1, 2013, 16:41 ET
- Period: 2013-03-31
- Accession: 0000064803-13-000005
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/64803/000006480313000005/cvs20130331-10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/64803/000006480313000005/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2013-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2013-01-01 to 2013-03-31 | $30.76bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2013-01-01 to 2013-03-31 | $25.18bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2013-01-01 to 2013-03-31 | $5.58bn | us-gaap:GrossProfit |
| Operating income | 3 months, 2013-01-01 to 2013-03-31 | $1.70bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2013-01-01 to 2013-03-31 | $127.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2013-01-01 to 2013-03-31 | $617.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2013-01-01 to 2013-03-31 | $956.0m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months, 2013-01-01 to 2013-03-31 | $0.77 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2013-01-01 to 2013-03-31 | $0.78 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2013-01-01 to 2013-03-31 | 1,241,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2013-01-01 to 2013-03-31 | $1.64bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2013-01-01 to 2013-03-31 | $318.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2013-01-01 to 2013-03-31 | $277.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 3 months, 2013-01-01 to 2013-03-31 | $393.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2013-03-31 | $1.55bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2013-03-31 | $19.73bn | us-gaap:AssetsCurrent |
| Total assets | at 2013-03-31 | $66.07bn | us-gaap:Assets |
| Current liabilities | at 2013-03-31 | $13.20bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2013-03-31 | $9.35bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2013-03-31 | $12.0m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2013-03-31 | $300.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2013-03-31 | $38.21bn | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |

## Market risk

As filed, 289 characters.

As of March 31, 2013, the Company had no derivative financial instruments or derivative commodity instruments in place and believes that its exposure to market risk associated with other financial instruments, principally interest rate risk inherent in its debt portfolio, is not material.

## Controls and procedures

As filed, 4,245 characters.

**Evaluation of disclosure controls and procedures:** The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a-15 (f) and 15d-15(f)) as of March 31, 2013, have concluded that as of such date the Company’s disclosure controls and procedures were adequate and effective and designed to ensure that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.

**Changes in internal control over financial reporting:** There have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the three months ended March 31, 2013 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Part II Item 1

### Legal Proceedings

Certain legal proceedings in which we are involved are discussed in Part I, Item 3 of our 2012 Annual Report on Form 10-K. The following discussion is limited to certain recent developments concerning our legal proceedings and should be read in conjunction with those earlier reports.

1\. In April 2009, the State of Texas filed a purported civil enforcement action against Caremark for injunctive relief, damages and civil penalties in Travis County, Texas alleging that Caremark violated the Texas Medicaid Fraud Prevention Act and other state laws based on our processing of Texas Medicaid claims on behalf of PBM clients on one of Caremark's adjudication platforms. In September 2011, the Company prevailed on a motion for partial summary judgment against the State of Texas and narrowed the remaining claims in the lawsuit. In October 2009 and October 2010, the Company received civil investigative demands from the Office of the Attorney General of the State of Texas requesting, respectively, information produced under the OIG subpoena and other information related to the processing of Medicaid claims. These civil investigative demands state that the Office of the Attorney General of the State of Texas is investigating allegations currently pending under seal relating to two other adjudication platforms of Caremark. In March 2013, the Company settled all matters related to Caremark's processing of Texas Medicaid claims.

2\. The Company received a subpoena from the U.S. Securities and Exchange Commission ("SEC") in February 2011 and has subsequently received additional subpoenas and other requests for information. The SEC's requests related to, among other things, public disclosures made by the Company during 2009, transactions in the Company’s securities by certain officers and employees of the Company during 2009 and the purchase accounting for the Longs Drug Stores acquisition. The Company has provided the documents and other information requested by the SEC and has been cooperating with the SEC in this investigation.

### Part II Item 2

### Unregistered Sales of Equity Securities and Use of Proceeds

(c) Stock Repurchases

The following table presents the total number of shares purchased in the three months ended March 31, 2013, the average price paid per share and the approximate dollar value of shares that still could have been purchased at the end of the applicable fiscal period, pursuant to the 2012 Repurchase Program. See Note 3 to the condensed consolidated financial statements.

| Fiscal Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs |
| --- | ---: | ---: | ---: | ---: |
| January 1, 2013 through January 31, 2013 | 1,955,500 | $49.87 | 1,955,500 | $4,571,552,451 |
| February 1, 2013 through February 28, 2013 | 122,574 | $51.01 | 122,574 | $4,565,299,731 |
| March 1, 2013 through March 31, 2013 | 5,308,200 | $54.54 | 5,308,200 | $4,275,791,520 |
| Totals | 7,386,274 |  | 7,386,274 |  |

30

### Part II Item 6

### Exhibits

Filed May 1, 2013.
Source: SEC EDGAR, the filing index for accession 0000064803-13-000005. Last ingested by Listed: Nov 6, 2026, 17:47 ET. No prices; not investment advice.
